# Clinical Significance of Bone Metastases in Pleural Mesothelioma

**Authors:** Mitsutomi Miyake, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otuski, Yoshiki Negi, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Yasuhiro Nakajima, Daichi Fujimoto, Kazuhiro Kitajima, Toshiyuki Minami, Takashi Kijima

PMC · DOI: 10.1111/1759-7714.70033 · Thoracic Cancer · 2025-03-11

## TL;DR

This study found that 11.5% of pleural mesothelioma patients develop bone metastases, which are linked to worse survival and non-epithelial tumor types.

## Contribution

The study identifies non-epithelial histology as a novel independent risk factor for bone metastases in pleural mesothelioma.

## Key findings

- Bone metastases occurred in 11.5% of pleural mesothelioma patients.
- Non-epithelial histology was an independent risk factor for bone metastases.
- Patients with bone metastases had worse overall survival (18.6 vs. 21.7 months).

## Abstract

Bone metastasis (BoM) is common in advanced cancer, but its incidence in pleural mesothelioma (PM) remains unclear. This study aimed to determine the incidence of BoM in PM patients and assess its prognosis and risk factors to clarify its clinical significance.

A retrospective analysis was conducted on 515 histologically confirmed PM patients enrolled between January 2011 and December 2020. The cumulative incidence of BoM was calculated using the Kaplan–Meier method, with group differences assessed via log‐rank tests. Risk factors for BoM were evaluated using multivariate logistic regression.

The median follow‐up was 13.3 months (range: 0.2–106.7 months). BoM was detected in 59 patients (11.5%) at diagnosis or during disease progression. Multivariate analysis identified non‐epithelial histology (odds ratio [OR]: 2.189, 95% confidence interval [CI]: 1.179–4.065, p = 0.013) as an independent risk factor for developing BoM. Patients with BoM had worse overall survival (OS) compared to those without BoM (median OS: 18.6 months vs. 21.7 months, p = 0.03).

BoM in PM occurs less frequently than in primary lung cancer, with non‐epithelial histology being more commonly associated with BoM. Patients with BoM had a poor prognosis, particularly when BoM was present at diagnosis. This study is limited by its retrospective design, which may introduce biases related to data collection and patient selection. Future prospective studies are needed to validate these findings.

Bone metastasis (BoM) was observed in 11.5% of pleural mesothelioma (PM) patients, with non‐epithelial histology being an independent risk factor for developing BoM. Patients with BoM had significantly worse survival outcomes compared to those without BoM.

## Linked entities

- **Diseases:** pleural mesothelioma (MONDO:0003308)

## Full-text entities

- **Diseases:** lung cancer (MESH:D008175), BoM (MESH:D009362), PM (MESH:D000086002), cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11894435/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11894435/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC11894435/full.md

---
Source: https://tomesphere.com/paper/PMC11894435